Press Releases

PRESS RELEASE: Veterans Exploring Treatment Solutions (VETS) Announces 4th Annual Torchbearer Ball to End Veteran Suicide

On November 15, 2025, the 4th Annual Torchbearer Ball returns to the iconic Hotel del Coronado. Hosted by Veterans Exploring Treatment Solutions (VETS), this black-tie gala gathers 600+ guests to honor veteran advocates, raise vital funds for psychedelic-assisted therapies, and advance the mission to end veteran suicide. This year’s Torchbearer Award will recognize filmmakers Jon Shenk and Bonni Cohen for their documentary In Waves and War, highlighting the healing journeys of Special Operations veterans.

Beyond the One Dose Wonder: Why Psychedelic Clinical Trial Protocols Must Evolve Beyond Academic Norms

When most people hear about psychedelic clinical trials, they envision a single, transformative session, maybe two, resulting in rapid, life-changing outcomes. But the reality is more complex.

Veterans Exploring Treatment Solutions (VETS) Takes Center Stage at Psychedelic Science 2025

Veterans Exploring Treatment Solutions (VETS) brought its mission to the forefront at Psychedelic Science 2025, spotlighting the urgent need for access, equity, and innovation in veteran mental health. From policy advocacy to powerful storytelling, VETS delivered a bold message: healing is a right—and veterans deserve the freedom to pursue it.

Press Release: VETS Co-Founder & CEO Amber Capone Named to Inc.'s 2025 Female Founders 500 List

Amber Capone, Co-Founder and CEO of VETS, has been named to Inc.'s 2025 Female Founders 500 List. This recognition highlights her significant contributions and leadership in her field.

Press Release: Veterans Exploring Treatment Solutions (VETS) Leads Legislative Day of Action on March 18, 2025 in Support of Texas Ibogaine Initiative

The Legislative Day of Action aims to educate legislators on the transformative potential of ibogaine-assisted therapy for veterans struggling with OUD, co-occurring SUD, and neurological or mental health conditions, as well as address the critical issue that service members must travel internationally to access these treatments.